Quick Dispatch:
Your tirzepatide cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics ships.
Need Help?
Questions about tirzepatide cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
29.33
❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on
25.47
Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats
20.98
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism
29.35
💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart
28.30
SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. “Cardiologists now have an ever-expanding
27.06
Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)
26.51
